Codexis to Commercially Supply Proprietary Enzyme to Tate & Lyle
December 06 2016 - 7:00AM
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company,
today announced that it has entered into an exclusive agreement
with Tate & Lyle, a global provider of ingredients and
solutions, to supply a proprietary enzyme for use in the company’s
food ingredient production.
“We are delighted to move our partnership with Tate & Lyle
to the commercial level,” said Codexis President and CEO John
Nicols. “This agreement further validates the ability of our
CodeEvolver® protein engineering platform technology to improve and
support manufacturing processes, in this case in the food industry.
Expanding application of our technology to new markets has been a
strategic priority for Codexis and establishing this agreement is a
notable achievement.”
About CodeEvolver® Protein Engineering Platform
TechnologyCodeEvolver® is Codexis’ proprietary protein
engineering platform, which enables the rapid development of
custom-designed enzymes that are highly optimized for a specific
function. The CodeEvolver® platform is comprised of proprietary
methods for the optimization of proteins through the design and
generation of diverse genetic libraries, automated screening
techniques, algorithms for the interpretation of screening data and
predictive modelling. The CodeEvolver® platform technology is
covered by approximately 225 issued patents and pending patent
applications worldwide.
About Codexis, Inc.Codexis, Inc. is a leading
protein engineering company that applies its technology to the
development of biocatalysts for commercial manufacture of
pharmaceuticals and fine chemicals. Codexis’ proven technology
enables implementation of biocatalytic solutions to meet customer
needs for rapid, cost-effective and sustainable manufacturing. For
more information, see www.codexis.com.
About Tate & LyleTate & Lyle is a
global provider of ingredients and solutions to the food, beverage
and other industries, with operations in over 30 locations
worldwide.
Tate & Lyle operates through two global divisions,
Speciality Food Ingredients and Bulk Ingredients, supported by our
Innovation and Commercial Development and Global Operations
groups.
The Group's strategy is to become a leading global provider of
Speciality Food Ingredients through a disciplined focus on growth,
and by driving Bulk Ingredients for sustained cash generation to
fuel this growth.
Speciality Food Ingredients consists of three platforms:
Texturants, which includes speciality starches and stabilisers;
Sweeteners, which comprises nutritive sweeteners and our range of
no-calorie sweeteners including SPLENDA® Sucralose; and our
Health and Wellness portfolio which includes speciality fibres and
our salt-reduction offering. Additionally, our Food Systems
business provides a wide variety of blended ingredient
solutions.
Tate & Lyle Bulk Ingredients includes bulk sweeteners,
industrial starches and fermentation products (primarily
acidulants). Corn co-products from both divisions are primarily
sold as animal feed.
Tate & Lyle is listed on the London Stock Exchange under the
symbol TATE.L. American Depositary Receipts trade under TATYY. In
the year to 31 March 2016, Tate & Lyle sales totalled £2.4
billion. For more information, please visit
http://www.tateandlyle.com
SPLENDA® is a trademark of Heartland Consumer Products
LLC.
Forward-Looking StatementsThis press release
contains forward-looking statements relating to Codexis’ supply
agreement with Tate & Lyle, including Codexis’ belief that this
agreement further validates the ability of our CodeEvolver® protein
engineering platform technology to improve and support
manufacturing processes, in this case in the food industry. You
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties and
other factors that are, in some cases, beyond Codexis’ control and
that could materially affect actual results. Factors that could
materially affect actual results include Codexis’ dependence on its
licensees and collaborators; Codexis’ dependence on a limited
number of products and customers in its pharmaceutical business;
potential adverse effects to Codexis’ business if its customers’
pharmaceutical products are not received well in the markets;
Codexis’ ability to deploy its technology platform in new market
spaces; Codexis’ dependence on key personnel; Codexis’ ability to
compete may decline if it loses some of its intellectual property
rights; third party claims that Codexis infringes third party
intellectual property rights; and Codexis could face increased
competition if third parties misappropriate Codexis biocatalysts.
Additional factors that could materially affect actual results can
be found in Codexis’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 8, 2016 and in Codexis’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 8, 2016, including, in each case,
under the caption “Risk Factors.” Codexis expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
CONTACT:
Investors
LHA
Jody Cain, 310 691 7100
jcain@lhai.com
Media
That’s Nice
Guy Tiene, 212 366 4455
guy@thatsnice.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024